Suchergebnisse - "Pérez-de-Llano, Luis"

PubPharm (23)

1

Contribution of the Remission Concept to the Treatment of Asthma

enthalten in: Archivos de bronconeumologia | 2023

von Pérez-de-Llano, L. | Veiga-Teijeiro, I. | Dacal-Rivas, D.

2

Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER) : Data From the International Severe Asthma Registry

enthalten in: The journal of allergy and clinical immunology. In practice | 2023

von Chen, W. | Tran, T. | Sadatsafavi, M. | +62

CommentIn: J Allergy Clin Immunol Pract. 2024 Feb;12(2):535-536. - PMID 38336402

3

Factors associated with suboptimal response to monoclonal antibodies in severe asthma

enthalten in: Allergy | 2023

von Pérez de Llano, L. | Marina Malanda, N. | Urrutia, I. | +10

4

Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

enthalten in: Allergy | 2023

von Pfeffer, P. | Ali, N. | Murray, R. | +66

5

Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

enthalten in: The journal of allergy and clinical immunology. In practice | 2022

von Porsbjerg, C. | Menzies-Gow, A. | Tran, T. | +56

ErratumIn: J Allergy Clin Immunol Pract. 2022 Jun;10(6):1673. - PMID 35688511

6

Eosinophilic and Noneosinophilic Asthma : An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort

enthalten in: Chest | 2021

von Heaney, L. | Perez de Llano, L. | Al-Ahmad, M. | +46

CommentIn: Chest. 2021 Sep;160(3):789-790. - PMID 34488949

7

Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma : The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

enthalten in: The journal of allergy and clinical immunology. In practice | 2021

von Pérez de Llano, L. | Dávila, I. | Martínez-Moragón, E. | +43

8

Treatment of Moderate-severe Asthma : An Alternative Strategy to the Guidelines Recommendations

enthalten in: Archivos de bronconeumologia | 2021

von Pérez de Llano, L. | Quirce Gancedo, S. | Plaza Moral, V.

9

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

enthalten in: Allergy | 2020

von Agache, I. | Beltran, J. | Akdis, C. | +31

10

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma : A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

enthalten in: Allergy | 2020

von Agache, I. | Rocha, C. | Beltran, J. | +31